Stay updated on Epacadostat + Sirolimus in Advanced Malignancy Clinical Trial

Sign up to get notified when there's something new on the Epacadostat + Sirolimus in Advanced Malignancy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Epacadostat + Sirolimus in Advanced Malignancy Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent change in the webpage content.
    Difference
    0.1%
    Check dated 2024-06-13T21:40:48.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a small phase I study with dose escalation and dose expansion cohorts in advanced malignancy, focusing on the combination of Epacadostat (IDO1 inhibitor) with Sirolimus (mTOR inhibitor) for patients with advanced solid tumor and non-small cell lung cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:35:42.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of eligibility criteria, explaining that researchers look for people who fit specific descriptions based on factors like general health or prior treatments. This change provides more context and examples of what eligibility criteria entail.
    Difference
    49%
    Check dated 2024-05-22T21:19:24.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:47:33.000Z thumbnail image

Stay in the know with updates to Epacadostat + Sirolimus in Advanced Malignancy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Epacadostat + Sirolimus in Advanced Malignancy Clinical Trial page.